tbuckley/cabot-search huggingface dataset:
Adverse Reactions to Humanized Monoclonal Antibodies
Authors: Dasha Roa-Medellin, Irene Garcia-Gutierrez, Maria C. Lillo, Marcos Sanchez-Dominguez, Arantza Ais-Larisgoitia, Pharm, Maria L. Baeza, Pilar Tornero
Journal: Journal of Allergy and Clinical Immunology (2017)
Nephrotoxicity induced by long term administration of VEGFR inhibitors for metastatic renal cell carcinoma
Authors: Ryosuke Oki, Yuji Miura, Yukinori Ozaki, Yuko Tanabe, Kazuhiro Kurosawa, Shinji Uragami, Toshikazu Okaneya, Toshimi Takano
Journal: Annals of Oncology (2016)
Long term survival of vinorelbine (N) and trastuzumab (H) as first line therapy for HER2-positive metastatic breast cancer patients (HER2+MBC) (pts)
Authors: A. Chan, L. Petruzelka, M. Untch, M. Martin, M. Gil Gil, V. Guillem Porta, M. Z. Wojtukiewicz, A. Stewart, D. Aubert, J. Gasmi
Journal: Journal of Clinical Oncology (2005)

587 Background: Preclinical studies show synergistic activity between N and H and several clinical trials have confirmed that this combination is active and safe for HER2+MBC patients. Here we report results of a large multinational, prospective phase II trial. Methods: MBC patients overexpressing HER2 (IHC 3+ or FISH + by centralised testing), with measurable disease, KPS > 70%, normal LVEF, no prior H or N, adjuvant chemotherapy allowed, were treated with N: 30 mg/m2/week and H: 4 mg/kg on day 1 as loading dose and then 2 mg/kg/w starting on day 8 (4 weeks = 1 cycle). Patients were reassessed every 2 cycles. Results: Between October 2000 and June 2002, 69 pts were included in the study (from 147 screened pts), median age 53 years (30–74), prior neo/adjuvant chemotherapy: 65.2% (anthracycline: 51.1%, anthracycline + taxanes: 28.9%, CMF: 20%), prior hormonal therapy: 49.3%, visceral metastasis: 75.4% (liver: 55.1%, lung: 29%). Sixty-six patients were evaluable for response and 68 pts for toxicity. The overall response rate is 61%, disease control (CR+PR+SD) is 79%. The median time to response is 8.4 weeks, median duration of response is 12 months and 1 year progession-free survival is 39%. After median follow-up of 29 months, the median survival is 24.5 months (95% CI, 18.4–37.5). The median duration of treatment is 25 weeks with a median of 7 cycles/pt, 3 pts were treated with this combination for more than 1 year and 2 pts are still receiving treatment. The regimen is safe: 17.7% grade 3–4 neutropenia events observed over 1686 courses with 2 episodes of febrile neutropenia, grade 3 H infusion reactions (1.5% of pts); asthenia (8.8% of pts); neuropathy (4%); no severe nausea, vomiting or alopecia; 3 pts experienced asymptomatic decline of LVEF below 50% that resolved after discontinuation of H for one cycle and treatment was reintroduced without further complication. Only one pt came off study due to grade 3 symptomatic cardiac dysfunction that resolved with therapy. Conclusion: Our results confirm that N + H is one of the most active treatment regimens for pts with HER2 positive MBC and demonstrates a very favourable safety profile allowing prolonged treatment with a long term survival. Author Disclosure Employment or Leadership Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Institut de Recherche Pierre Fabre Christie Hospital Christie Hospital Christie Hospital
Creation of On-PROST: The Ontario patient-reported outcomes of symptoms and toxicity applied clinical research unit.
Authors: Geoffrey Liu, Doris Howell, Andrea Perez Cosio, Monika K. Krzyzanowska, Madeline Li, Gary Rodin, Michael Donald Brundage, Andrew J. Hope
Journal: Journal of Clinical Oncology (2012)

47 Background: The 14 Ontario Regional Cancer Centers serve a catchment of 13 million people, centrally coordinated by Cancer Care Ontario. Since 2009, computer kiosks collect the Edmonton Symptom Assessment System (ESAS) patient reported outcomes (PROs). At specific centers, additional PROs such as the Distress Assessment and Response Tool (DART) have been integrated. On-PROST was created in 2011 to customize PROs for disease-, treatment- and phase-specific symptoms and toxicities, and to address core multidimensional impacts of cancer. On-PROST aims to improve patient experience and quality of care through routine collection of standardized sets of PROs for combined use in clinical care and research. Methods: On-PROST structure has five research pillars, each dependent on quality PROs: Health Services Research; Biomarker Research; Radiation Oncology; Palliative/Supportive Care; and the PROs-Cancer Core items. National/international partnerships are being established to develop, standardize and implement PROs relevant across the entire cancer continuum. Results: National consensus was generated for the implementation of the Canadian PROMs-Cancer Core. Key domains on physical, emotional and social health were included, and implementation testing has begun. In parallel, specific On-PROST sub-projects have focused on identifying, validating, and standardizing logic-based sets of PROs for disease-, treatment- and phase-specific symptoms and toxicities. On-PROST projects have focused on topics that complement existing research by other groups (PROMIS, PRO-CTCAE). Initial projects have included: (i) assessment of dysphagia and related symptoms in head and neck and esophageal cancer populations; (ii) short/long term sexual function in prostate and testicular cancers; (iii) a lung cancer radiogenetic toxicity study; and (iv) patient reported outcomes related to physical activity and other modifiable behaviors after cancer diagnosis. Conclusions: The multi-pronged structure of On-PROST will systematically collect disease-, treatment-, and phase-specific PROs at a population level.
Final Results of a Phase 1-2 Study of Vorinostat (SAHA), Cladribine, and Rituximab (SCR) Relapsed B-Cell Non-Hodgkin’s Lymphoma and Previously Untreated Mantle Cell Lymphoma
Authors: Stephen Spurgeon, Kamal Sharma, David F. Claxton, Christopher Ehmann, Sara Shimko, August Stewart, Samir Parekh, Violetta V. Leshchenko, Yiyi Chen, Motomi Mori, Jeffrey J. Pu, Elliot Epner
Journal: Blood (2014)
Rapid and Sustained Engraftment of a Single Allogeneic Ex-Vivo Expanded Cord Blood Unit (CBU) After Reduced Intensity Conditioning (RIC) in Adults. Preliminary Results of a Prospective Trial
Authors: Noel Milpied, Bernard Dazey, Zoran Ivanovic, Pascale Duchez, Stephane Vigouroux, Reza Tabrizi, Arnaud Pigneux, Marie-Sarah Dilhuydy, Krimo Bouabdallah, Thibaut Leguay, Mathieu Sauvezie, Xavier Lafarge, Gerald Marit, Jean-Michel Boiron
Journal: Blood (2011)
The Use of Reduced Intensity Allogeneic Stem Cell Transplantation (alloSCT) for Recurrence after Autologous Stem Cell Transplantation (ASCT) in Hodgkin’s Disease (HD).
Authors: Amrita Y. Krishnan, Auayporn Nademanee, Henry C. Fung, Leslie Popplewell, Roberto Rodriguez, Zaid Al Kadhimi, Mark Kirschbaum, Neil Kogut, Andrew Raubitschek, Jeffrey Schriber, Jasmine Zain, Eileen Smith, Nigel Cheng, Dajun Qian, Arturo Molina, Stephen J. Forman
Journal: Blood (2004)
Preliminary results of a randomized phase II study: Treatment of Chinese patients with advanced gastric cancer with FOLFIRI followed by FOLFOX7 or the reverse sequence.
Authors: F. Bi, Q. Li, C. Zhou, J. Yu, X. Cai, M. Qiu, J. Liu, C. Yi, D. Luo, F. Xu
Journal: Journal of Clinical Oncology (2011)

4064 Background: Two regimen sequences: folinic acid, 5-fluorouracil (FU), and irinotecan (mFOLFIRI) followed by folinic acid, FU, and oxaliplatin (mFOLFOX7; arm A), or mFOLFOX7 followed by mFOLFIRI (arm B) were evaluated for their anti-tumor activity and toxicity in Chinese patients (pts) with locally advanced and metastatic gastric cancer. Methods: Previously untreated pts with gastric or gastro-esophageal junction adenocarcinoma were randomized (1:1) to above two regimen sequences, as described in ASCO 2010 (TPS207). Results: 145 pts, 71 in arm A and 74 in arm B, were included between April 2008 and September 2010. Demographic characteristics were comparable (arm A vs arm B), age: 53 vs 52; M/F: 71%/29% vs 73%/27%; PS 0-1: 52% vs 53%; metastatic: 92% vs 91%; primary tumor resected: 69% vs 66%. All the pts received at least one cycle in 1st line. The 1st-line treatments were well tolerated in both arms without treatment-related death. National Cancer Institute Common Toxicity Criteria grade 3-4 neutropenia (34%) and grade 3 sensory neuropathy (12%) were more frequent with mFOLFOX7. However, pts in mFOLFIRI group experienced more grade 3 delayed diarrhea (6%) and grade 2 alopecia (45%). Other frequently reported adverse events were predominantly grade1 or 2, included thrombocytopenia, anemia, nausea, anorexia, fatigue, stomachache, mucositis, and liver function abnormalities, without difference between two arms. 32% and 34%, in arm A and arm B, respectively, of chemotherapies were delayed because of toxicity. Dose reduction was reported in 14 cases in arm A and 6 cases in arm B. Conclusions: Both regimens were well-tolerated with acceptable and manageable toxicities. The first-line therapy efficacy is being followed up and will be presented at the meeting.
Correlation between TP53 Deletion and Protein Overexpression in Chronic Lymphocytic Leukaemia and Its Impact on Prognostic.
Authors: Paloma Martin, Toon Min, Alison Morilla, Sarah Hockley, Ayoma D. Attygale, John Swansbury, Claire Dearden, Andrew Wotherspoon, Gareth Morgan, Estella Matutes
Journal: Blood (2007)
P08.58 Upfront chemotherapy in grade III gliomas: an institutional retrospective series
Authors: F. Bruno, M. Magistrello, F. Franchino, A. Pellerino, E. Nicolotto, D. Garbossa, L. Bertero, P. Cassoni, R. Rudà, R. Soffietti
Journal: Neuro-Oncology (2016)

chondrial-mediated) pathway was activated at 24 hours as shown by elevation of caspase 8, 9 and 3/7 levels.The reduction in cell viability in response to clomipramine was attenuated by the pan-caspase inhibitor Z-VAD-FMK, indicating involvement of caspases in the mechanism of action.With the most significant effects observed with SEBTA-023; 24 hours at 75µM clomipramine cell viability increased by 50% and 67% under hypoxic and normoxic conditions respectively (p<0.0001).The effects on the cell cycle were evaluated and clomipramine treatment led to cell cycle arrest in G2/M phase.Two other tricyclic antidepressants, imipramine and amitriptyline were also examined and clomipramine was deemed to be the most effective inducer of apoptosis.CONCLUSIONS: This work provides further insights to the mechanism of action of this class of repurposed drug as a potential adjuvant treatment for GBM. P08.
Patient-reported outcomes (PROs), unmet need, and psychosocial adaptation among recent breast cancer (BC) survivors.
Authors: Steven C Palmer, Angela DeMichele, Marilyn M. Schapira, Karen Glanz, Abigail Blauch, Donna A. Pucci, Linda A. Jacobs
Journal: Journal of Clinical Oncology (2016)

212 Background: BC survivors have physical and psychosocial symptoms which, if unaddressed, result in unmet need. Unmet need has been examined primarily in long term survivors, and understanding the characteristics associated with unmet need is under-studied among recent patients. Methods: Eligibility included non-metastatic BC treated &lt; 1 year prior. Participants completed a PRO symptom measure and reported unmet need for assistance for symptoms. Concerns about recurrence risk, late effects, health maintenance, family needs, and hereditary risks were assessed. Anxiety and depressive symptoms were assessed using the HADS; quality of life (QoL),using the SF-12. Results: Participants (N = 137) were primarily white (72%), middle-aged (M = 55 yrs), and treated for Stage I (47%) or II (38%) BC. Participants reported an average of 10.7 symptoms (R = 0-18), while unmet need was less common (M = 2.6, R = 0-15). Physical and mental health QoL were similar to norm values (M = 48.0; M = 53.5). 13% and 29% met “caseness” (i.e., criteria for significant elevation) for depression or anxiety on the HADS, respectively. Unmet need was trichotomized into no (0), low (1-3), and elevated (4-15) groups. Level of unmet need was not predicted by demographic variables, time from end of treatment, treatment exposure, staging, or physical QoL. Groups differed significantly with respect to level of patient concern, mental health QoL, anxiety and depression, and meeting caseness for depression on the HADS (all p &lt; 0.03) with elevated needs being associated with worse outcomes. In multivariate analysis, overall unmet need was independently predicted by depression and level of survivorship concerns (R 2 = .28, p &lt; .001). Conclusions: In the year after treatment, patient reported symptoms are common, but unmet need is less common. QoL is similar to national norms. Higher unmet need is associated with worse psychosocial adaptation, including QoL, patient concerns, anxiety, and depression. In particular, depression and survivorship concerns independently predict unmet need. Addressing unmet needs among recent BC survivors may be one means of improving the psychological functioning of these survivors.
Prevalence, clinico-pathological features and outcomes of ‘double-hit’ high-grade B-cell non-Hodgkins lymphoma (NHL): a single institution experience
Authors: D.J. McHugh, P. Gou, J. Quinn, P. Thornton, B. Bird, S. Sukor, A. Fortune, K. Perera, L. Bacon, E. Vandenberghe, R. Flavin, C. Grant
Journal: Annals of Oncology (2016)
GSK-3 Spatial Regulation Has an Essential Role in Lenalidomide Activity and Represents a Biomarker of Clinical Response in CLL
Authors: Suzanne Trudel, Sam Scanga, Fabrizio G Mastronardi, Ellen Nong Wei, Frank Mercurio, Antonia Lopez-Girona, Svetlana Gaidarova, David R. Webb, Christine Chen, Keith Stewart, Armen S Manoukian
Journal: Blood (2012)
RTHP-34. PLACEMENT OF SCALP ELECTRODES (NOVO TTF) DOES NOT SIGNIFICANTLY CHANGE RADIATION DOSIMETRY WHEN DELIVERING CRANIAL INTENSITY MODULATED RADIATION THERAPY (IMRT)
Authors: Gaurav Shukla, Joshua Palmer, Taoran Li, Virginia Lockamy, Cheng Peng, Wenyin Shi
Journal: Neuro-Oncology (2016)

A recent phase III trial in patients with glioblastoma demonstrated survival benefit with tumor treating fields (NovoTTF) after completion of post-operative chemoradiation. There may be benefit to utilizing NovoTTF during radiation therapy. We investigate whether placement of the NovoTTF transducer arrays during radiation delivery impacts dosimetry. We generated radiation plans using a cranial phantom with and without NovoTTF transducer arrays in place for five tumor locations based on real patient data. All plans were generated using VMAT (volume modulated arc therapy) with sparing techniques on phantoms with NovoTTF arrays. The plans were then applied to phantoms with NovoTTF transducer arrays. Key dosimetric parameters, including planning target volume (PTV) coverage, dose to organs at risk, mean scalp dose, and scalp D10cc / D20cc, etc were collected and compared. Verification of dosimetric results was done through OSL and film measurement. Mean scalp dose was 13.1Gy +/- 3.3 Gy with scalp sparing VMAT technique. The placement of NovoTTF transducer arrays did not significantly affect the PTV coverage by the prescription dose, minimum PTV dose, or mean PTV dose. Doses to avoidance structures including the brainstem, optic chiasm, lens, and spinal cord were slightly lower with the placement of NovoTTF transducer arrays; however, these were non-significant. OSL and film measurement confirmed the findings from dosimetric comparison. In a cranial radiation phantom model, the presence of NovoTTF transducer arrays does not impact radiation dosimetry. The impact would be even less in actual patient treatment due to frequent change of arrays with slight shift in placement.
Health-Related Quality of Life (HRQoL) and Changes in Work Productivity Measures with Subcutaneous C1-Inhibitor [C1-INH(SC)] for the Prevention of Hereditary Angioedema (HAE) Attacks: Findings from the Compact Study
Authors: William Lumry, Timothy J. Craig, Henriette Farkas, Henrike Feuersenger
Journal: Journal of Allergy and Clinical Immunology (2017)
Polypoid lesions from the oesophagus to colon
Authors: Po-Jui Huang, Chia-Lun Chang, Fat-Moon Suk
Journal: Gut (2017)

A 73-year-old man presented with abdominal fullness for 2 months. He had lost 5 kg in the previous 2 months. He did not have fever or abdominal pain. He had a history of chronic hepatitis B. Physical examination showed enlarged lymph nodes over bilateral neck, axillary and inguinal areas. Laboratory study revealed leucocytosis with white cell counts 14.1×109/L; haemoglobin level 12.8 g/dL; platelet count 227×109/L; hypoalbuminaemia with albumin level 2.8 g/dL, as well as normal blood sugar, aminotransferase, urea, creatine, serum uric acid and lactic acid dehydrogenase levels. Tumour markers carcinoembryonic antigen, carbohydrate antigen 19–9 and alpha-fetoprotein were all within normal limits. The upper GI panendoscopy showed …
Open-Label, Prospective, Multicentre, Phase I/II Study of AOP2014, a Novel PEG-Proline-Interferon Alpha-2b in Patients with Polycythemia Vera: Update from an Ongoing Study
Authors: Heinz Gisslinger, Robert Kralovics, Renate Schoder, Bettina Gisslinger, Veronika Buxhofer-Ausch, Karin Strecker, Dominik Wolf, Ella Willenbacher, Richard Greil, Alexander Egle, Thomas Melchardt, Sonja Burgstaller, Franz-Josef Tarmann, Christoph Wachter, Oleh Zahriychuk, Josef Thaler
Journal: Blood (2011)
Autologous Stem Cell Transplantation (ASCT) with Busulfan Plus Cyclophosfamide as Conditioning Regimen for Acute Myeloid Leucemia: Retrospective Experience (1991–2007) of Two Bone Marrow Transplant Unit
Authors: Giuseppe Irrera, Giuseppe Messina, Massimo Martino, Giuseppe Console, Giuseppe Milone, Pasquale Iacopino
Journal: Blood (2008)
DC/Aml Fusion Cell Vaccination Administered to AML Patients Who Achieve a Complete Remission Potently Expands Leukemia Reactive T Cells and Is Associated with Durable Remissions
Authors: Jacalyn Rosenblatt, Richard M. Stone, Lynne Uhl, Donna Neuberg, Poorvi Somaiya, Dina Stroopinsky, Robin Joyce, James D. Levine, Jon E. Arnason, Katarina Luptakova, Malgorzata McMasters, Salvia Jain, David P. Steensma, Daniel J. DeAngelo, Ilene Galinsky, Aya Sato-Dilorenzo, Kristen Anna Palmer, Emma Logan, Mary Paty Bryant, Donald Kufe, David Avigan
Journal: Blood (2015)
Determinants for the decision of chemotherapy in advanced cancer patients.
Authors: Charles Velter, Helene de-La-Menardiere, Francois Goldwasser
Journal: Journal of Clinical Oncology (2014)

110 Background: Chemotherapy is often prescribed in order not to despair a patient in an advanced stage of cancer, while the physician identifies an unfavorable benefit/risk ratio. The use of chemotherapy in terminally ill cancer patients in the last months of life is associated with an increased risk of aggressive care (Wright A et al. BMJ; 348:g1219 doi: 10, 2014). We previously showed that multidisciplinary meetings with palliative specialists reduce futility (Colombet I et al. BMJ Support Palliat Care; 2(3):239-47, 2012). We studied the parameters leading to inappropriate palliative chemotherapy in France: How oncologists face to unrealistic expectations and what is the process for the decision-making leading to chemotherapy beyond evidence-based medicine? Methods: The study was conducted in April 2014 in Paris, France. We designed a Multiple Choice Questionnaire. The first part described a clinical situation of a patient with advanced pancreatic cancer with evidence-based factors for not doing chemotherapy. The second part included questions regarding the behavior of the oncologist. Results: We included 62 oncologists. While 58 oncologists (94%) considered beneficial to include palliative medicine specialists, 44 (71%) chose to prescribe cytotoxic chemotherapy. In the decision-making process, 49 oncologists (79%) gave more weight to the demand of the patients than to the benefit/risk ratio. The validated scores for the evaluation of life-expectancy in this setting were not known in 19 cases (31%). In advanced disease, 42 oncologists (68%) acknowledged to decide without multidisciplinary staff meeting. Conclusions: The decision-making in advanced disease tended to be solitary. Cytotoxic chemotherapy appears as a common answer to unrealistic expectations. Multidisciplinary meetings with palliative medicine specialists are recommended to improve end-of-life decisions.
The effector capacity of peripheral blood mononuclear cells (PBMCs) from HER2+ breast cancer (BC) patients treated with chemotherapy and HER2-targeted therapies (ICORG 10-05)
Authors: N. Gaynor, A. Canonici, A. Eustace, M. McDermott, N. O'Donovan, J. Crown, D.M. Collins
Journal: Annals of Oncology (2016)
Prognostic Value of Neuro-Psychological and Biological Factors in Clinically Fit Older Patients with Hematological Malignancies
Authors: Stéphanie Dubruille, Yves Libert, Marie Maerevoet, Myriam Roos, Aurélie Collard, Sandrine Vandenbossche, Nathalie Meuleman, Darius Razavi, Dominique Bron
Journal: Blood (2014)
Patients hospitalized abroad as importers of multiresistant bacteria—a cross-sectional study
Authors: T. Khawaja, J. Kirveskari, S. Johansson, J. Väisänen, A. Djupsjöbacka, A. Nevalainen, A. Kantele
Journal: Clinical Microbiology and Infection (2017)

The pandemic spread of multidrug-resistant (MDR) bacteria poses a threat to healthcare worldwide, with highest prevalence in indigent regions of the (sub)tropics. As hospitalization constitutes a major risk factor for colonization, infection control management in low-prevalence countries urgently needs background data on patients hospitalized abroad.We collected data on 1122 patients who, after hospitalization abroad, were treated at the Helsinki University Hospital between 2010 and 2013. They were screened for methicillin-resistant Staphylococcus aureus (MRSA), extended-spectrum β-lactamase-producing Enterobacteriaceae (ESBL-PE), vancomycin-resistant enterococci, carbapenemase-producing Enterobacteriaceae (CPE), multiresistant Pseudomonas aeruginosa and multiresistant Acinetobacter baumannii. Risk factors for colonization were explored by multivariate analysis.MDR colonization rates were higher for those hospitalized in the (sub)tropics (55%; 208/377) compared with temperate zones (17%; 125/745). For ESBL-PE the percentages were 50% (190/377) versus 12% (92/745), CPE 3.2% (12/377) versus 0.4% (3/745) and MRSA 6.6% (25/377) versus 2.4% (18/745). Colonization rates proved highest in those returning from South Asia (77.6%; 38/49), followed by those having visited Latin America (60%; 9/16), Africa (60%; 15/25) and East and Southeast Asia (52.5%; 94/179). Destination, interhospital transfer, short time interval to hospitalization, young age, surgical intervention, residence abroad, visiting friends and relatives, and antimicrobial use proved independent risk factors for colonization.Post-hospitalization colonization rates proved higher in the (sub)tropics than elsewhere; 11% (38/333) of carriers developed an MDR infection. We identified several independent risk factors for contracting MDR bacteria. The data provide a basis for infection control guidelines in low-prevalence countries.